anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is a prospective,observational,cohort study. Data of post-cardiac surgical patients who receives noninvasive ventilation (NIV) in the investigators' cardiac surgical intensive care unit are prospectively collected into a database for further analyzation since January 2018. Tolerance of NIV is estimated by a four-point NIV intolerance score system: A score of 1 indicates a comfortable and relaxed patient tolerating NIV; a score of 2 indicates mild intolerance with some discomfort and occasional grabbing at the NIV mask; a score of 3 indicates moderate intolerance and discomfort with the NIV mask most of the time with frequent grabbing at the mask (sometimes pulling it off); and a score of 4 indicates severe NIV intolerance with agitation or/and an inability to leave the NIV mask in place. Participants who receives re-intubation will be recorded as 4 points. Application of remifentanil or dexmedetomidine will be initiated when a score of 3 or 4 was recorded, according to the intensivists' preference.Depending on the sedation regime applied, patients with NIV intolerance are divided into two groups: remifentanil group and dexmedetomidine group.The investigators will compare the two groups with the NIV intolerance score at 15min,1, 3, 6, 12, 24, 48, 60 and 72 hours after the initiation of the sedation regime. The investigators will also compare the two groups with clinical outcomes such as NIV failure, tracheotomy rate, mortality, ICU length of stay etc.
This group will receive isotonic saline at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
FIELD: medicine. SUBSTANCE: invention relates to agent influencing cardiovascular system. Invention proposes agent made as tabletted form and covered by envelope. Tablet core comprises nifedipin as an active component and the following accessory substance: lactose, microcrystalline cellulose, potato starch, crospovidone, polyvinylpyrrolidone and magnesium state. Tablet envelope comprises hydroxypropylmethylcellulose, polyethylene glycol, talc, titanium dioxide and due. Agent elicits low toxicity and on the base experimental studies it is referred to IV class of low toxic medicinal substances. EFFECT: valuable medicinal properties, low toxicity of agent. 1 dwg, 17 tbl
Sports medicine providers often perform various outpatient procedures to manage musculoskeletal and neuropathic conditions. Vasovagal syncope is a rare but a possible complication. Convulsive syncope is one subtype that involves brief extensor stiffening and nonsustained myoclonus and can be easily mistaken for seizures. We present a case series of convulsive syncope as a complication of common sports medicine outpatient procedures. We aim to describe how to identify this condition, and offer risk stratification and management strategies to mitigate the risks of this complication. Sports medicine providers who routinely practice outpatient procedures should be aware of this complication. Simple changes in approaching the procedure may mitigate these risks. High- and intermediate-risk features of the syncopal episode should prompt physicians to seek further evaluation by a specialist to rule out more serious conditions. In all instances, appropriate on-site support and equipment for emergent resuscitation and management should be prepared.
Various embodiments relate to compounds, having structures according to Structure A or Structure B, as specified herein. The compounds according to various embodiments may inhibit NT5C2 nucleotidase. The compounds according to various embodiments may synergistically decrease cell viability of NT5C2 R367Q mutant lymphoblasts when used in combination with 6-mercaptopurine (6-MP) to treat a cancer. The cancer may be, but is not limited to, acute lymphoblastic leukemia. Various embodiments relate to a compositions that may include one or more compounds according to any embodiment described herein or a pharmaceutically acceptable salt or derivative thereof and a pharmaceutically acceptable carrier. Various embodiments relate to methods of treating cancer. The method may comprise administering a therapeutically effective amount of one or more compounds according to any embodiment described herein or a pharmaceutically acceptable salt or derivative thereof.
An injectable essentially non aqueous (i.e. having a water content of 0 - 10%) medicinal composition, comprises at least one of the oil soluble vitamin A esters chosen from the propionate, butyrate and valerate and an oil- and water-soluble polyoxethylene material, in conc. of at least 25% by weight of the vitamin(s) and may be up to 20 times the vitamin(s) weight. The polyoxethylene material may be a polyoxyethylene sorbitan fatty acid ester or a polyoxyethylated vegetable oil, these promote absorption of the vitamin A esters. In addition the composition may contain vitamin A acetate and/or vitamin D or E active cpds. an antioxidant, an antimicrobial and a viscosity reducing agent. Such cpsns. are useful in veterinary medicine, for supplying in an injectable formulation, vitamin A esters, to cattle poultry and domestic animals.
A pharmaceutical oral controlled release multiple-units formulation is prepared by mixing units containing an active substance and coated with a substantially water-insoluble, but water diffusable controlled release coating with particles of an active substance, the mean size of which is at least one power of 10 smaller than the coated units under conditions which will result in adherence of the smaller particles to the surface of the controlled release coating in a substantially uniform layer. The coated units have a mean size of between about 0.1 and 1.5 mm, in particular about 0.4 to 1.2 mm, and the fine particles have a mean particle size of from about 1 to about 50  mu m and are present in the composition in an amount of at the most 25 percent by weight, in particular at the most 5 percent by weight and preferably not more than 1 percent by weight, calculated on the weight of the coated units. The mixing is performed in the presence of an anti-adhesive which counteracts undesired electrostatic charging such as talc or colloidal silicon dioxide. The active substance which is subject to controlled release may be potassium chloride, and the active substance of the small particles may be a diuretic. The controlled release coating contains a film-forming polymer such as ethyl cellulose, a plasticizer and a hydrophobic substance. In this manner, it is possible to combine an active substance which it is preferred to administer in a controlled release multiple-units composition, for example because it has an irritating effect on the gastric mucosa or because it has a short half life, with an instantly releasing active substance to obtain a combination composition which simplifies the dosing regimen and thus improves patient compliance.
PURPOSE:To obtain a post-treating agent for a cysteamine hair processing agent, containing at least one selected from an acid and salt under prescribed conditions and freed of unpleasant smell emitted after subjecting the hair to hair processing using the cysteamine hair processing agent. CONSTITUTION:The objective substance, containing at least one selected from an acid (e.g. citric or malic acid) and a salt (e.g. NaOH or KOH) and obtained by dissolving and blending the acid at pH 2-2.7 in an amount of 0.1-0.5 milliequiv. based on 1ml, as necessary, suitably blending a surfactant, a hair growth agent such as urea, higher alcohol or amino acid, a preservative, a colorant, a perfume, etc., and preparing a post-treating agent. If the post-treating agent is used after completing treatment with the second agent in a method for processing the hair using the cysteamine hair processing agent, unpleasant smell can be inhibited. Furthermore, if the first agent containing a keratin hydrolyzate blended therein as the cysteamine hair processing agent is used, effects of the post-treating agent are synergized.
An x-ray apparatus and method can improve x-ray imaging in a variety of ways. For example, the improve x-ray apparatus can reduce scatter from x-ray images acquired by two-dimensional detectors. An improved 2D x-ray apparatus can provide 3D imaging for medical and/or industrial applications. An improved 2D x-ray apparatus and method can produce separate material imaging, and composition analysis for characterization and correlation of image, densitometry, and composition information of individual component or individual material within a single subject. Non-rotational 3D microscopy, combining 2D or 3D full field x-ray imaging and high resolution 2D or 3D x-ray microscopy or spectral absorptiometry and spectroscopy can achieve a higher resolution and wider field of view in x-ray imaging and quantitative analysis in 3D and real time. The x-ray apparatus can improve tracking and/or surgical guidance in time and/or space.
This study consists of 2 parts. In first part, healthy adult participants will receive a single nasal dose of JNJ-43260295 or placebo in a double blind (both the participant and investigator do not know whether participant is assigned to receive study medication or placebo), randomized (study medication or placebo assigned to participants by chance), and placebo-controlled (study in which the experimental treatment or procedure is compared to a placebo) setting. In second part, which will be open label (participants and investigators are aware about the treatment, participants are receiving), atopic participants with mild to mild-persistent asthma will participate in 3 consecutive treatment periods (Period 1, 2, and 3). In Period 1, each participant will receive a single nasal dose of JNJ-43260295 without prior nasal allergen challenge. In Period 2, each participant will receive a single nasal dose of JNJ-43260295, preceded by a nasal allergen challenge approximately 15 hours prior to the JNJ-43260295 dosing. In Period 3, each participant will receive single nasal allergen challenge without JNJ-43260295. There will be a washout period of at least 21 days between 3 consecutive treatment periods. Cytokine levels in nasal lavage and gene expression in nasal scraping will be primarily evaluated during all treatment periods. Participants' safety will be monitored throughout the study.
Cannabidiol (CBD) for use in the treatment of childhood onset epilepsy in patients who are concurrently taking clobazam characterised in that the patient is monitored for incidence of pneumonia, is provided. Preferably the dose of CBD is between 5 and 50mg/kg/day, and the dose is preferably reduced by 10% and 90%. The dose of clobazam is preferably between 5 and 60mg/kg/day, and the dose is preferably reduced by between 10% and 90%. The CBD may be in the form of a highly purified extract of cannabis which comprises at least 95% (w/w) CBD, or the CBD may be in the form of a synthetic compound. The childhood onset epilepsy is preferably selected from: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex (TSC). A method of treating childhood onset epilepsy in an individual in need thereof, comprising administering to the patient a therapeutically effective amount of cannabidiol with caution, wherein the individual is concurrently taking clobazam is outlined, wherein the caution preferably comprises monitoring the individual for adverse events.
BACKGROUND: Stress hyperphenylalaninemia predicts elevated mortality rates in patients with acute decompensated heart failure (ADHF). This study investigated the metabolic pathways underlying this association and identified a unique metabolic phenotype underlying the association between stress hyperphenylalaninemia and adverse outcomes in ADHF.
METHODS AND RESULTS: This was a retrospective cohort study. We enrolled 120 patients with ADHF in an intensive care unit (60 with a phenylalanine level ≥112 μM, 60 with a phenylalanine level <112 μM), and 30 controls. Plasma phenylalanine-derived metabolites were measured, and participants were evaluated for 30-day death. Patients with ADHF had extensive activations of the alternative pathways for metabolizing phenylalanine, leading to the levels of phenylalanine-derived downstream metabolites 1.5 to 6.1 times higher in patients with ADHF than in the controls (all P<0.001). Extensive dysregulation of these alternative pathways significantly increased phenylalanine levels and contributed to a distinct metabolic phenotype, characterized by increased phenylalanine, tyrosine, homogentisic acid, and succinylacetone levels but decreased benzoic acid and 3,4-dihydroxyphenylalanine levels. Throughout the 30-day follow-up period, 47 (39.2%) patients died. This distinct metabolic phenotype was associated with an increased mortality rate (odds ratio, 1.59 [95% CI, 1.27-1.99]; P<0.001). A multivariable analysis confirmed the independent association of this metabolic phenotype, in addition to phenylalanine and tyrosine levels, with 30-day death.
CONCLUSIONS: In patients with ADHF, extensive dysregulation of the alternative pathways for metabolizing phenylalanine was correlated with stress hyperphenylalaninemia and a distinct metabolic phenotype on the phenylalanine-tyrosine-homogentisic acid-succinylacetone axis. Both stress hyperphenylalaninemia and metabolic dysregulation on this axis were associated with poor outcomes.
Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.
During the first 5-6 weeks of the study standard of care will be conducted as usual practice by the medicine teams at MSKCC. It is expected that during that time they will care for at least 20 LEP patients who meet our inclusion criteria. There are no specific target numbers for any of the included languages. During the following 5-6 weeks, the phones will be installed by the 10 house-staff teams and approximately an additional 20 LEP patients who meet the protocol inclusion criteria will be enrolled. Therefore, in the first half of this study about 20 LEP patients and 40 practitioners (two practitioners per LEP patient) will provide data and the same numbers will account for the second half of the study after the intervention is instituted. There will be no randomization of patients or physicians. The only data that will be analyzed are those questions from the surveys to assess communication effectiveness with LEP patients. The number of patients who are interviewed will depend on MSKCC inpatient census at the time of study.
Drug: Docetaxel and cisplatin TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
The American College of Emergency Physicians (ACEP) Emergency Medicine Quality Network (E-QUAL) Opioid Initiative was launched in 2018 to advance the dissemination of evidence-based resources to promote the care of emergency department (ED) patients with opioid use disorder. This virtual platform-based national learning collaborative includes a low-burden, structured quality improvement project, data benchmarking, tailored educational content, and resources designed to support a nationwide network of EDs with limited administrative and research infrastructure. As a part of this collaboration, we convened a group of experts to identify and design a set of measures to improve opioid prescribing practices to provide safe analgesia while reducing opioid-related harms. We present those measures here, alongside initial performance data on those measures from a sample of 370 nationwide community EDs participating in the 2019 E-QUAL collaborative. Measures include proportion of opioid administration in the ED, proportion of alternatives to opioids as first-line treatment, proportion of opioid prescription, opioid pill count per prescription, and patient medication safety education among ED visits for atraumatic back pain, dental pain, or headache. The proportion of benzodiazepine and opioid coprescribing for ED visits for atraumatic back pain was also evaluated. This project developed and effectively implemented a collection of 6 potential measures to evaluate opioid analgesic prescribing across a national sample of community EDs, representing the first feasibility assessment of opioid prescribing-related measures from rural and community EDs.
Didanosine Delayed-Release Capsules are available as:

200 mg: Two-piece hard gelatin capsule with green opaque cap and white opaque body filled with white pellets. Imprinted in black ink barr over 200 mg on one piece and 588 on the other piece. 

250 mg: Two-piece hard gelatin capsule with blue opaque cap and white opaque body filled with white pellets. Imprinted in black ink barr over 250 mg on one piece and 589 on the other piece.

400 mg: Two-piece hard gelatin capsule with red opaque cap and white opaque body filled with white pellets. Imprinted in black ink barr over 400 mg on one piece and 590 on the other piece.
Workflows for automatic measurement of Doppler is provided. In various embodiments, a plurality of frames of a medical video are read. A mode label indicative of a mode of each of the plurality of frames is determined. At least one of the plurality of frames is provided to a trained feature generator. The at least one of the plurality of frames have the same mode label. At least one feature vector is obtained from the trained feature generator corresponding to the at least one of the plurality of frames. At least one feature vector is provided to a trained classifier. A valve label indicative of a valve is obtained from the trained classifier corresponding to the at least one of the plurality of frames. One or more measurement is extracted indicative of a disease condition from those of the at least one of the plurality of frames matching a predetermined valve label.
A bioerodible controlled drug release implant is produced which contains a suitable pharmaceutically active compound dispersed uniformly throughout a polymeric matrix. An implant is prepared by dissolving a suitable bioerodible polymer in an organic solvent followed by the addition of a predetermined amount of a pharmaceutical preparation. The solution is mixed until the polymer and drug are fully dissolved. The solution is then evaporated to dryness where the dry polymer/drug composition is reduced to a granular composition which is then formed by compression molding into the desired shaped. The pharmaceutical preparation may be a drug in pure form or a solution of a drug dissolved in a suitable solvent. In the event the solution of the drug is immiscible with the polymer solution a suitable dispersing agent is included in the drug solution to disperse the drug with the polymer. Devices formed by the method are suitable for controlled drug release devices, bone or other prosthesis and the like.
Safety and effectiveness in pediatric patients have not been established. Modafinil is not approved in this population for any indication.

Serious skin rashes, including erythema multiforme major (EMM) and Stevens-Johnson Syndrome (SJS) have been associated with modafinil use in pediatric patients [see Warnings and Precautions (5.1)].

In a controlled 6 week study, 165 pediatric patients (aged 5 to 17 years) with narcolepsy were treated with modafinil (n=123), or placebo (n=42). There were no statistically significant differences favoring modafinil over placebo in prolonging sleep latency as measured by MSLT, or in perceptions of sleepiness as determined by the clinical global impression-clinician scale (CGI-C).

In the controlled and open-label clinical studies, treatment emergent adverse reactions of the psychiatric and nervous system included Tourette’s syndrome, insomnia, hostility, increased cataplexy, increased hypnagogic hallucinations, and suicidal ideation. Transient leukopenia, which resolved without medical intervention, was also observed. In the controlled clinical study, 3 of 38 girls, ages 12 or older, treated with modafinil experienced dysmenorrhea compared to 0 of 10 girls who received placebo.

There were three 7 to 9 week, double-blind, placebo-controlled, parallel group studies in children and adolescents (aged 6 to 17 years) with Attention-Deficit Hyperactivity Disorder (ADHD). Two of the studies were flexible-dose studies (up to 425 mg/day), and the third was a fixed-dose study (340 mg/day for patients <30 kg and 425 mg/day for patients ≥30 kg). Although these studies showed statistically significant differences favoring modafinil over placebo in reducing ADHD symptoms as measured by the ADHD-RS (school version), there were 3 cases of serious rash including one case of possible SJS among 933 patients exposed to modafinil in this program. Modafinil is not approved for use in treating ADHD.
Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
Normal wear-and-tear on the knee can cause tissue, or cartilage, in the knee to soften over time forming chondral lesions. Worn out cartilage is often found during knee surgery for other conditions. Typically, surgeons will remove any worn out cartilage that is found using a procedure called debridement. However, the investigators do not know if surgically treating the worn out cartilage is better than leaving the tissue untreated, so it is necessary to compare the two. Patients who are found to have worn out cartilage during arthroscopy, will be randomly assigned to either receive treatment (debridement) or non-treatment (observation) of their cartilage. Patients without worn out cartilage will also be included in this study and observed postoperatively.

The primary objective of this study is to examine the effects of treatment of worn out cartilage (versus non-treatment of worn out cartilage and versus patients without worn out cartilage), on self-reported knee pain following arthroscopic meniscectomy using a double-blinded randomized controlled trial design. Secondary objectives of this study include examining the effects of treating worn out cartilage on other outcomes (subjective knee and general health scores and knee measurements including range of motion, presence of effusion and quadriceps circumference) and also to calculate the intra-operative costs associated with treatment, including the amount of time and instruments needed for debridement.